Anti-viral action against Type 1 diabetes autoimmunityGPPAD-05-AVAnT1A

Klinikum rechts der Isar der TU Muenchen AöR0 个研究点目标入组 2,252 人开始时间: 2023年12月8日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Ages between 3.00 and 4.00 months at the time of enrollment, A high genetic risk (>10%) to develop islet autoantibodies by age 6 years as determined by a HLA DR/DQ genotype, polygenic risk score and first-degree family history of type 1 diabetes status, Written informed consent signed by the custodial parent(s)

•Any medical condition, concomitant disease or treatment that may interfere with the assessments or may jeopardize the participant’s safe participation in the study. These include immune deficiencies, and conditions or treatments that lead to immune suppression., Likely poor compliance due to expected change in residency., Diagnosis of diabetes prior to recruitment or randomisation, Current use of any other investigational drug, Previous hypersensitivity to the excipients of the vaccine

发起方

Klinikum rechts der Isar der TU Muenchen AöR